Skip to main content

inbrx-106

·Code: INBRX-106

inbrx-106: 2 clinical trials tracked.

inbrx-106 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about inbrx-106, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors
Clinical Trial Registry Records (2)

A Phase II, Single-arm, Multi-center, Open-label Study of Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as an Induction Immunotherapy for Stage II/III TNBC Patients

NCT06353997Registry updated 2026-09-16·Phase 2
Recruiting

Primary endpoint: Volumetric Response

Interventionalopen12 targetStarted 2024-09Completion 2029-063 sites · United StatesProvidence Health & Services

A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (HexAgon-HN)

NCT06295731Registry updated 2026-05-08·Phase 2/Phase 3·INBX
Active, not recruiting

Primary endpoint: Phase 2: Objective Response Rate (ORR)

InterventionalRandomizeddouble410 targetStarted 2024-05Completion 2029-0550 sites · Australia, Belgium, Bulgaria, France…Inhibrx Biosciences, Inc